Hypertensive pregnancy disorders (HPD) are important causes of maternal and fetal morbidity and mortality worldwide. In addition, a history of HPD has been associated with an increased risk for maternal cardiovascular disease later in life, possibly due to irreversible vascular and metabolic changes that persist beyond the affected pregnancies. Therefore, treatment of HPD may not only improve immediate pregnancy outcomes, but also the maternal long-term cardiovascular health. Unlike the recommendations for hypertension treatment in the general population, treatment recommendations of HPD have not changed substantially for more than two decades. This is particularly true for mild to moderate hypertension in pregnancy, defined as a blood pressure of 140–159/90–109 mm Hg.This review focuses on the goals of therapy, treatment strategies, and new developments in the field of HPD that should be taken into account when considering blood pressure targets and pharmacological options for treatment of hypertension in pregnant women.
展开▼
机译：高血压妊娠疾病（HPD）是全球母婴发病率和死亡率的重要原因。此外，HPD的病史与生命后期母亲心血管疾病的风险增加有关，可能是由于不可逆的血管和代谢变化持续到受影响的妊娠期以外。因此，HPD的治疗不仅可以改善即刻妊娠结局，而且可以改善孕妇的长期心血管健康。与一般人群中高血压治疗的建议不同，HPD的治疗建议已经超过二十年没有实质性改变。这对于怀孕的轻度至中度高血压尤为如此，其定义为血压为140–159 / 90–109 mm Hg。本综述着重于治疗的目标，治疗策略以及HPD领域中的新发展，在考虑血压目标和治疗孕妇高血压的药理选择时应予以考虑。
展开▼
